Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astria Therapeutics ( (ATXS) ) has issued an update.
On January 23, 2026, Astria Therapeutics completed its merger with BioCryst Pharmaceuticals, with Astria surviving as a wholly owned subsidiary after Axel Merger Sub, Inc. was merged into Astria. At the effective time of the transaction, each outstanding share of Astria common stock (other than shares held by the companies and dissenting holders) was converted into the right to receive a mix of BioCryst common stock and cash consideration, while Astria’s preferred stock, options and warrants were treated in accordance with the merger terms. Concurrently, Astria joined as a guarantor to a new $400 million term loan facility entered into by BioCryst with Blackstone-affiliated lenders, maturing on January 23, 2031, providing substantial long-term financing backing the combined company. As a result of the deal, Astria’s Nasdaq listing was suspended and the company moved to delist and deregister its common stock, terminating its public reporting obligations, while its prior board members and executive officers resigned and were replaced by BioCryst designees, with Astria’s charter and bylaws also amended to align with its new private, subsidiary status.
The most recent analyst rating on (ATXS) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.
Spark’s Take on ATXS Stock
According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.
The score is held down primarily by weak financial performance—minimal revenue, large losses, and rising cash burn—despite low leverage. Technicals are mixed with softer near-term momentum but a still-positive longer-term trend, while valuation support is limited by the negative P/E and no dividend. Corporate events modestly lift the outlook due to the approved acquisition, tempered by merger-related litigation risk.
To see Spark’s full report on ATXS stock, click here.
More about Astria Therapeutics
Astria Therapeutics, Inc. is a Delaware-incorporated biopharmaceutical company that, prior to the merger, was listed on the Nasdaq Global Market and operated as an independent publicly traded entity before becoming a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc.
Average Trading Volume: 1,078,503
Technical Sentiment Signal: Hold
Current Market Cap: $710.1M
Learn more about ATXS stock on TipRanks’ Stock Analysis page.